 |
|
|
| |
Dolutegravir in Key Demographic Subgroups of Treatment-Experienced HIV-Infected Populations
|
| |
| |
Reported by Jules Levin
53rd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 10-13, 2013; Denver, CO
Debbie Hagins,1AdrianoLazzarin,2Princy Kumar,3Paul Sax,4John Lombaard,5Beatriz Grintzjein,6Pedro Cahn,7DavidDorey,8 Jane Yeo,9Sandy Griffith,10Sherene Min,10on behalf of the extended SAILING and VIKING-3 Teams
1Chatham CARE Center, Savannah, GA, USA; 2San Raffaele Scientific Institution, Milan, Italy; 3Georgetown University Hospital, Washington, DC, USA; 4Brigham and Women's Hospital, Boston, MA, USA; 5Josha Research, Bloemfontein, South Africa; 6Instituto de Pesquisa Clínica Evandro Chagas Fiocruz, Rio de Janeiro, Brazil; 7Fundación Huésped, Buenos Aires, Argentina; 8-10GlaxoSmithKline, 8Mississauga, Canada; 9Stockley Park, UK; 10Research Triangle Park, NC, USA
|
| |
|
|
|
|
|
